Ovarian Stimulation Outcomes During a GnRH Antagonist Protocol for In-vitro Fertilization When Comparing Trigger Day Decision by Physicians Versus an Artificial Intelligence-based Algorithm.

NCT ID: NCT07110285

Last Updated: 2026-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-21

Study Completion Date

2028-05-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the number of mature oocytes following a GnRH antagonist in-vitro fertilization stimulation cycle when comparing trigger day timing decision by physicians versus an artificial intelligence-based algorithm

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Examination of all patients undergoing an ovarian stimulation cycle utilizing the GnRH antagonist protocol for oocyte cryopreservation or for fertilization via intracytoplasmic sperm injection (ICSI) (any treatment where oocytes are denuded and maturity may be assessed). The number of mature oocytes will be compared between cycles where trigger day timing was decided by the treating physician versus an artificial intelligence-based algorithm.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IVF Outcomes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Physician-based trigger day timing decision

Trigger day timing is decided on by the treating physician

Group Type NO_INTERVENTION

No interventions assigned to this group

Artificial intelligence-based algorithm trigger day timing decision

Trigger day timing decision by an artificial intelligence-based algorithm

Group Type EXPERIMENTAL

Artificial intelligence-based algorithm

Intervention Type OTHER

Trigger day timing decision by an artificial intelligence-based algorithm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artificial intelligence-based algorithm

Trigger day timing decision by an artificial intelligence-based algorithm

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients undergoing an ovarian stimulation cycle utilizing the GnRH antagonist protocol for oocyte cryopreservation or for fertilization via intracytoplasmic sperm injection (ICSI) (any treatment where oocytes are denuded and maturity may be assessed).

Exclusion Criteria

* Loss to follow-up, patient retracts consent to participate
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

FertilAI

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michal Youngster

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ariel Hourvitz, MD

Role: PRINCIPAL_INVESTIGATOR

Herzeliya Medical Center, Israel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Herzliya Medical Center

Herzliya, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michal Youngster, MD

Role: CONTACT

+972-50-643-0111

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michal Youngster

Role: primary

0506430111

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0015-23-HMC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gonadotropin Type in Ovarian Stimulation
NCT02437032 COMPLETED PHASE4
Antagonist Protocol in IVF
NCT02335736 UNKNOWN PHASE2